PDF DatasheetAntibody (Suitable for clinical applications)
| Specification | Recommendation |
|---|---|
| Recommended Dilution (Conc) | 1:25-1:50 |
| Pretreatment | Citrate Buffer pH 6.0 |
| Incubation Parameters | 30 min at Room Temperature |
Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.
CA 19-9 Information for Pathologists
Summary:
Modified Lewis(a) blood group antigen secreted by or expressed on the surface of cancer cells. Used primarily as a serum tumor marker to screen for pancreatic cancer and to monitor effectiveness of therapy. However, only 50 – 75% sensitive for initial screening of pancreatic cancer and relatively nonspecific. Terminology Carbohydrate Antigen 19-9.
Notable Clinical Features:
Used primarily as a serum biomarker. As a serum screening test for pancreatic cancer, is more sensitive than CEA but less sensitive than CXCL8 (Pol Arch Intern Med 2018 Jul 27 [Epub ahead of print]). Used to screen for pancreatic cancer but has limited sensitivity and specificity. May also be elevated in patients with cholangiocarcinoma or colon cancer. Serum levels also elevated in cirrhosis, cholestasis and pancreatitis but values are usually below 1,000 U/mL.
| CA 19-9 General Information | |
|---|---|
| Alternate Names | |
| Curated Database and Bioinformatic Data | |
| UniProt ID(s) | N/A |
| General Description of CA 19-9 . | |
| This antibody reacts specifically with sialyl Lewisa and recognizes an epitope being designated CA 19-9. It does not cross-reacts with Lewisa and Lewisb. CA 19-9 has been shown to be useful marker in the diagnosis and management of gastrointestinal cancers. | |
There are no reviews yet.